Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

Prohost Letter #396

June 6, 2016 0

Prohost Letter #396 CELEBRATING MEMORIAL DAY - Wish you celebrated the Memorial Day. Memorial Day’s purpose was …

At ASCO: Exelixis Has Great News for Cobimetyx on RCC

June 6, 2016 0

Additional data from pivotal METEOR trial underscore clinically meaningful benefit of Exelixis’ (EXEL) drug Cabometyx™ for …

Theravance Biopharma and Mylan COPD Product is Speeding Towards Approval

June 3, 2016 0

Enrollment has been completed in all the three ongoing clinical trials comprising the firm’s Phase 3 …

Biomarin Decision Might Add More Stress Than Put Pressure on the FDA to Approve Sarepta Drug

June 2, 2016 0

Biomarin Pharmaceutical’s (BMRN) decision to withdraw its DMD drug Kyndrisa™ (drisapersen) Marketing Authorization Application (MAA) from …

IONIS Stock Selloff: Has GSK Abandoned the Wagon or Jumped Out of the Train? See Also: Osteoporosis

May 27, 2016 0

Ionis Pharmaceuticals (IONS) stock plummeted when GlaxoSmithKline (GSK) stopped pursuing a late stage trial of Ionis-TTR …

Great News for Innoviva and COPD Patients

May 25, 2016 0

GlaxoSmithKline and Innoviva: The COPD inhaler Relvar® Ellipta® (known as Brio Ellipta in the United States) …

Exelixis: Results Demonstrate the Potential of Cabozantinib to Become the Gold Standard First Line Treatment for Advanced RCC

May 23, 2016 0

Yes, indeed, the good news has come from the randomized CABOSUN phase 2 trial with Exelixis’ …

Accelerated FDA Approvals of Immunotherapy Treatments Are Accelerating

May 19, 2016 0

CANCER Everyday something new is discovered that explains cancer behavior, including proliferation, response to treatment, resistance …

Portola: Solving the Huge Problem of the New Anticoagulants

May 18, 2016 0

Notwithstanding the unrelenting improvements being constantly made in managing blood coagulation’s problems, conventional anticoagulants still have …

Biogen: A Fruitful Collaboration in Gene Therapy. A Small Gene Therapy Firm That You Should Know

May 17, 2016 0

COLLABORATIONS Preparing for the Future, Biogen Signs a Lucrative Collaborative Agreements While Highlighting the Small Firm …

Disrupting the Capability of Cancer Cells to Repair Their Damaged DNA. See Also: Underestimated Biotech Firms

May 16, 2016 0

Underestimating the Value of Drugs that Disrupt the DNA Repair Mechanisms in Cancer Cells. AstraZeneca’s (AZN) Chief …

Seres Therapeutics Collaborates with Memorial Sloan Kettering Cancer Center to Improve Immunotherapy

May 13, 2016 0

Seres Therapeutics (MCRB), is microbiome therapeutics platform company. It focuses on developing a novel class of …

Giving to Gilead What Belongs to Gilead. Jazz Offers a Needed Relief

May 11, 2016 0

GILEAD After years of controversial refraining, official India reversed course and granted Gilead Sciences its patent …

Incyte Acquires Ariad Pharmaceuticals European Operations. See Also: A Great Achievement by Illumina

May 10, 2016 0

By June, which is next month, Incyte (INCY) will be the owner of the European operations …

Exelixis Again. The Road to Defeating DMD. Two New Important IPOs

May 9, 2016 0

EXELIXIS AGAIN They said: Sell EXEL, as no partner is interested in the firm’s FDA approved …

Prohost Letter #395

May 4, 2016 0

Prohost Letter #395 On the Road TO DEFEATING CANCER - Results of cancer treatment with novel immunotherapy …

A Judge is Offended About False Claims Against Gilead. Good News from Regeneron

May 2, 2016 0

GILEAD SCIENCES The people who cause the selloff of Gilead’s (GILD) stock because it missed 5 …

Who Will End Up Acquiring Medivation? Abbott Acquires St Jude. See Also: Alnylam

April 28, 2016 0

Medivation is a Target for Acquisition The Question is: Who Will Acquire Medivation? Sanofi has made a bid …

Agenus First Immune Check Protein Inhibitor in Clinical Trial. See Also: IMGN and EXEL

April 27, 2016 0

Biotech NEWS AGENUS Agenus’ First Checkpoint Inhibitor to reach Clinical Trial The first patient has …

The FDA Approval of Exelixis Drug Cabometyx™ Is Indeed Great News

April 26, 2016 0

Congratulations. The FDA approved Exelixis’ (EXEL) drug Cabometyx™ (cabozantinib) tablets for advanced renal cell carcinoma …

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd